These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19679211)

  • 1. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.
    Glover SJ; Eastell R; McCloskey EV; Rogers A; Garnero P; Lowery J; Belleli R; Wright TM; John MR
    Bone; 2009 Dec; 45(6):1053-8. PubMed ID: 19679211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Recker RR; Marin F; Ish-Shalom S; Möricke R; Hawkins F; Kapetanos G; de la Peña MP; Kekow J; Farrerons J; Sanz B; Oertel H; Stepan J
    J Bone Miner Res; 2009 Aug; 24(8):1358-68. PubMed ID: 19338452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A; Glover SJ; Eastell R
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Eastell R; Chen P; Saag KG; Burshell AL; Wong M; Warner MR; Krege JH
    Bone; 2010 Apr; 46(4):929-34. PubMed ID: 20060078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PINP as an aid for monitoring patients treated with teriparatide.
    Tsujimoto M; Chen P; Miyauchi A; Sowa H; Krege JH
    Bone; 2011 Apr; 48(4):798-803. PubMed ID: 21168536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.
    Eastell R; Krege JH; Chen P; Glass EV; Reginster JY
    Curr Med Res Opin; 2006 Jan; 22(1):61-6. PubMed ID: 16393431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study.
    Ardawi MS; Maimani AA; Bahksh TA; Rouzi AA; Qari MH; Raddadi RM
    Bone; 2010 Oct; 47(4):804-14. PubMed ID: 20659600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study.
    Garnero P; Mulleman D; Munoz F; Sornay-Rendu E; Delmas PD
    J Bone Miner Res; 2003 Oct; 18(10):1789-94. PubMed ID: 14584889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis G; Kita M; Avramidis A
    Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bed rest during pregnancy on bone turnover markers in pregnant and postpartum women.
    Kaji T; Yasui T; Suto M; Mitani R; Morine M; Uemura H; Maeda K; Irahara M
    Bone; 2007 Apr; 40(4):1088-94. PubMed ID: 17229597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.
    Miyauchi A; Matsumoto T; Shigeta H; Tsujimoto M; Thiebaud D; Nakamura T
    J Bone Miner Metab; 2008; 26(6):624-34. PubMed ID: 18979163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.